Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dave Gore's Trades That Make Sense -- Ignore unavailable to you. Want to Upgrade?

To: Frederick Langford who wrote (9597)	7/17/2002 2:36:11 PM
From: Dave Gore	Respond to of 16631

True; also NOVN beginning to gain strength. Now back up to 11.22. Here's why I bought this "disaster" stock near $10 this morning: CNBC just put out a report that none of NOVN's patches were tested or found to be at fault, yet the stock tanked way more than WYE, especially today. Indeed patches may not even pose any risks. Here's why. NOVN said this - "It is not necessarily clear that the results obtained in the study are applicable to the other hormone replacement drugs. In a prepared statement, Noven pointed out that the WHI investigators noted that transdermal patches might have a different risk-benefit ratio because they better mimic the natural physiology of the sex hormones progestin and estrogen." NOVN also recently beat expectations and was just at $20 and guided strong going forward. This is the perfect type of play for me. I buy low and sell quick if it doesn't look to be working, but if I'm up I give it some time.